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SUPPLEMENT

Interventions for Individuals With High Levels of Needle Fear
Systematic Review of Randomized Controlled Trials
and Quasi-Randomized Controlled Trials
C. Meghan McMurtry, PhD, C Psych,*wz Melanie Noel, PhD,y
Anna Taddio, BScPhm, MSc, PhD,8z Martin M. Antony, PhD, C Psych,#
Gordon J.G. Asmundson, PhD, RD Psych,**
Rebecca Pillai Riddell, PhD, C Psych,zwwzz
Christine T. Chambers, PhD, R Psych,yy88 Vibhuti Shah, MD, MSc,zz##
and HELPinKids&Adults Team
Background: This systematic review evaluated the eﬀectiveness of
exposure-based psychological and physical interventions for the
management of high levels of needle fear and/or phobia and
fainting in children and adults.
Design/Methods: A systematic review identiﬁed relevant randomized and quasi-randomized controlled trials of children, adults, or
both with high levels of needle fear, including phobia (if not
available, then populations with other speciﬁc phobias were
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included). Critically important outcomes were self-reported fear
speciﬁc to the feared situation and stimulus (psychological interventions) or fainting (applied muscle tension). Data were pooled
using standardized mean diﬀerence (SMD) or relative risk with
95% conﬁdence intervals.
Results: The systematic review included 11 trials. In vivo exposurebased therapy for children 7 years and above showed beneﬁt on
speciﬁc fear (n = 234; SMD:  1.71 [95% CI: 2.72, 0.7]). In
vivo exposure-based therapy with adults reduced fear of needles
posttreatment (n = 20; SMD:  1.09 [ 2.04, 0.14]) but not at
1-year follow-up (n = 20; SMD:  0.28 [ 1.16, 0.6]). Compared
with single session, a beneﬁt was observed for multiple sessions of
exposure-based therapy posttreatment (n = 93; SMD:  0.66
[ 1.08,  0.24]) but not after 1 year (n = 83; SMD:  0.37 [ 0.87,
0.13]). Non in vivo e.g., imaginal exposure-based therapy in children reduced speciﬁc fear posttreatment (n = 41; SMD:  0.88
[ 1.7,  0.05]) and at 3 months (n = 24; SMD:  0.89 [  1.73,
 0.04]). Non in vivo exposure-based therapy for adults showed
beneﬁt on speciﬁc fear (n = 68; SMD: 0.62 [ 1.11,  0.14]) but
not procedural fear (n = 17; SMD: 0.18 [ 0.87, 1.23]). Applied
tension showed beneﬁt on fainting posttreatment (n = 20; SMD:
 1.16 [ 2.12, 0.19]) and after 1 year (n = 20; SMD:  0.97
[ 1.91,  0.03]) compared with exposure alone.
Conclusions: Exposure-based psychological interventions and
applied muscle tension show evidence of beneﬁt in the reduction of
fear in pediatric and adult populations.
Key Words: fear, phobia, needle, blood-injection-injury, exposure,
applied tension

(Clin J Pain 2015;31:S109–S123)

N

eedle procedures are highly prevalent in childhood but
occur with high frequency across the lifespan in both
healthy individuals and those with chronic illnesses. At
approximately 12 billion injections per year, vaccinations
are the most common painful procedure worldwide.1 Fear
of needles is also common in children and adults and can
result in a host of deleterious consequences, including vaccination noncompliance and avoidance of health care.2–15
Needle fears are a known contributor to vaccine hesitancy,12
which is a pressing public health concern worldwide.16
Therefore, eﬀective management of needle fears has
important implications for improving global public health.
Fear of needles exists on a continuum ranging from
none or very little to severe needle fears that cause signiﬁcant distress and impairment (eg, noncompliance with
medical care resulting in adverse health outcomes).
www.clinicalpain.com |
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Individuals who have been diagnosed with blood-injectioninjury phobia (ie, the type of speciﬁc phobia that needle
phobia falls within in the Diagnostic and Statistical Manual
of Mental Disorders—5th Edition17) are at the severe end
of the needle fear spectrum. The lifetime prevalence of
blood-injection-injury phobia is approximately 3% to
4.5%.3,18,19 The prevalence rises when individuals who have
a high degree of needle fear, but not a diagnosis of needlerelated phobia, are considered (estimated at approximately
10% of the population).4–6,12 It is important to note that
individuals who have not been diagnosed with a needle
phobia or who would be considered below the diagnostic
threshold for the disorder are nevertheless at increased risk
for adverse outcomes. Indeed, they may have suﬃciently
elevated levels of anxiety and fear about needles that lead to
the avoidance of procedures entirely, their responses interfere
with clinicians’ ability to carry out procedures (eg, due to
fainting, ﬂailing, attempts to escape), or their fear impedes
the eﬃcacy of traditional interventions for procedural
pain.12,15,20 Individuals with high levels of needle fear who
also have chronic health conditions requiring injections (eg,
diabetes) are a particularly vulnerable group who require
treatment of their fear to maximize adherence to their medical regimen and avoid negative health eﬀects.6,15,21,22
In 2010, a multidisciplinary team from across Canada
published a clinical practice guideline on the management
of vaccination pain in infants and children.23 In 2013,
HELPinKIDS 2.0 (herein, HELPinKids&Adults) was
launched to address stakeholders’ interest in an update of
the knowledge synthesis to: (1) include trials that had been
published after 2010; (2) broaden the scope to include
adults; and (3) provide guidance on the management of
high levels of needle fear. It was recognized by this team
that individuals with a high degree of needle fear present a
signiﬁcant challenge to front line immunizers and that
traditional vaccination pain management strategies were
not appropriate for this particularly vulnerable population.
Interventions that hold particular promise for reducing
needle fears, as well as associated responses such as fainting,
in this highly fearful or phobic group of individuals are
exposure and applied tension (ie, muscle tension + exposure).
Exposure is a psychological intervention that is considered an
eﬃcacious treatment for speciﬁc phobias in general24–27 and
may be delivered in various formats (eg, in vivo, imaginal,
single session, multiple session). Exposure-based therapy
involves a hierarchical presentation of the feared stimulus.
For needle procedures, aspects of needle procedures would be
encountered in a hierarchical manner of ascending fear (eg,
sitting in the waiting room, to seeing a syringe without a
needle, to seeing a syringe with a needle, to holding a syringe
with a needle, to holding the tip of a needle against one’s arm,
and culminating in receipt of an injection). Exposure-based
therapy also frequently includes instruction, participant
modeling, and targeting of catastrophic thoughts (ie, cognitive distortions or thinking errors, such as magnifying the
threat of the needle) made by the individual. The exposure
must be of a suﬃcient duration that the individual’s fear
decreases, he or she realizes the “catastrophe” did not occur,
or that he or she can survive it (tests the catastrophic belief).28
Although phobias are often considered as a homogenous group, this may be an oversimpliﬁcation and obscure
important diﬀerences with implications for treatment,
particularly for fear relating to needles. For example,
individuals with high levels of needle fear or blood-injection-injury phobia have an increased risk of showing a

S110 | www.clinicalpain.com
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vasovagal response (fainting) when confronting the feared
situation3,5,10,11,29; indeed, this response is not seen in other
speciﬁc phobias. The vasovagal response is typically
described as diphasic (but see Ritz et al30); speciﬁcally, an
increase in blood pressure and heart rate is followed by an
overcompensatory, precipitous decrease in blood pressure
and heart rate leading to reduced cerebral blood ﬂow and
eventual loss of consciousness (fainting). Muscle tension is
a physical technique in which individuals are taught to: (1)
tense their muscles (eg, abdominal, legs, arms) to raise their
blood pressure and combat the vasovagal response; (2)
recognize prodromal signs of impending vasovagal syncope
(eg, visual disturbances, feeling dizzy, or clammy); and (3)
apply the technique when prodromal signs occur.31 Muscle
tension becomes “applied tension” when individuals practice the technique while being exposed to the object of their
fear (eg, needles). This technique has been recommended to
reduce fainting during voluntary blood donations32 and has
also been investigated within the context of needle fear and
fainting.30,33
There are narrative reviews on blood-injury phobia7,13
(as conceptualized in the Diagnostic and Statistical Manual
of Mental Disorders-III34), blood-injection-injury phobia6,10,11,14 as well as injection phobia.35 Ayala et al33
published a more recent systematic review focused on the
eﬃcacy of applied tension for adults with blood-injectioninjury phobia but did not provide a full meta-analysis. The
aforementioned reviews also focused almost exclusively on
adult populations with 2 exceptions, one of which is a brief
commentary,36 whereas the other is a narrative review.14
Although the reviews typically list a variety of treatments
that have been utilized for needle fear and needle phobia
(eg, exposure, systematic desensitization, modeling, relaxation training, education, reassurance, pharmacological
strategies including conscious sedation and anxiolytics,
distraction, hypnosis, general cognitive-behavioral strategies, family interventions6,7,10,11,13,14,35), none have provided a systematic review and full meta-analysis of treatments in the context of the quality of the original studies.
Furthermore, the management of these fears has never been
reviewed in relation to the vaccination context. In sum,
given the frequency of needle procedures, the consequences
of unmitigated pain and fear,20 and the lack of systematic
treatment evaluation, there is a clear and urgent need to
systematically synthesize the literature on the treatment of
high levels of needle fear, including, but not limited to,
needle phobia.
The current systematic review synthesized the evidence
for the following exposure-based, behavioral interventions
with respect to management of needle fear in children and
adults: (1) in vivo exposure (graduated exposure to the
actual feared stimulus); (2) multiple versus single sessions of
in vivo exposure; and (3) non in vivo exposure (indirect
exposure to the feared stimulus using computer-based
stimuli or individuals’ imaginations). In addition, applied
tension (muscle tension with exposure) versus exposure
alone was evaluated for reducing fainting among individuals with high needle fears.

METHODS
The current systematic review is part of a series of
reviews using consistent search strategy, data extraction
and pooling, and quality assessment processes following
both the Grading of Recommendations Assessment,
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TABLE 1. Clinical Questions and Outcomes

Clinical Questions
Interventions for individuals with high needle fear
Should in vivo exposure-based therapy be used for children Z7 y
with high levels of needle fear?
Should in vivo exposure-based therapy be used for adults with
high levels of needle fear?
Should multiple-session in vivo exposure-based therapy be used
(rather than single session) for children Z7 y and adults with
high levels of needle fear?
Should non in vivo (imaginal) exposure-based therapy be used
for children Z7 y with high levels of needle fear?
Should non in vivo exposure-based therapy be used for adults
with high levels of needle fear?
Should applied tension (exposure and muscle tension) be used
for children Z7 y and adults with high levels of needle fear
and fainting?

Development and Evaluation (GRADE37) and Cochrane
methodologies.38 Details of the overarching methodology
are provided elsewhere.39 Brieﬂy, the HELPinKids&Adults
Team was brought together to update and expand a previous knowledge synthesis and clinical practice guideline
and provide cutting edge guidance on the management of
vaccination pain across the lifespan as well as the management of high levels of needle fear. Consistent with the
GRADE process, the selection of clinical questions and
rating of the importance of outcomes was achieved using a
team-based voting approach (described in detail in Taddio
et al39). The systematic search strategy was developed by
evidence leads under the guidance of a librarian with
expertise in systematic reviews. The following databases
were searched: EMBASE, Medline, PsycINFO, CINAHL,
and ProQuest Dissertations & Theses Global. This broad
search strategy yielded a large number of results that were
screened for eligibility.39 Articles of potential interest to the
current systematic review were then screened again by 2
reviewers (C.M.M. and D.L., a research assistant).
Included articles were extracted in full on customized forms
by the lead author (C.M.M.) and checked by the second
author (M.N.).
The inclusion criteria for the current systematic review
were as follows: (1) participants were individuals with a high
degree of needle fear or phobia related to needles such as
blood-injection-injury phobia or injection phobia (in the
absence of data for individuals with needle fear, other speciﬁc
phobias were accepted) undergoing vaccination or next
closest procedure; (2) a randomized or quasi-randomized trial
examining exposure-based interventions with at least 5 participants per group; (3) measurement of an outcome of
interest; and (4) published report (short or full) or published
academic thesis. Of note, the inclusion of individuals with
non–needle-related speciﬁc phobias (eg, spider) occurred
solely for the clinical questions regarding children. The
pediatric treatment literature typically collapses across phobia subtypes (this was done in 3 of the 6 included trials; these
trials had the largest numbers of participants40–42) and
exposure-based treatments have been recommended for speciﬁc phobias in general.24,25 The foci of fear of participants of
included trials are described within each clinical question.
Critical outcomes (as voted upon by the HELPinKids&Adults Team) were speciﬁc fear (ie, fear particular
to the situation, object, or both that is the focus of the
Copyright

r

Critical
Outcomes
Fear
Fear
Fear
Fear
Fear
Fainting

Important Outcomes
Distress, pain, fainting, procedure outcomes, parent
fear, compliance, memory, preference, satisfaction
Distress, pain, fainting, procedure outcomes,
compliance, memory, preference, satisfaction
Distress, pain, fainting, procedure outcomes,
compliance, memory, preference, satisfaction
Distress, pain, fainting, procedure outcomes, parent
fear, compliance, memory, preference, satisfaction
Distress, pain, fainting, procedure outcomes,
compliance, memory, preference, satisfaction
Fear, distress, pain, procedure outcomes, compliance,
memory, preference, satisfaction

individual’s apprehension; ideally, this would be needle fear
but could be, for example, fear of spiders in individuals
diagnosed with a phobia of spiders) for the questions
relating to exposure therapy and fainting for the remaining
question on applied tension. Speciﬁc fear was typically
measured through multi-item questionnaires or using a
rating of acute fear during an imagined or actual engagement with the feared stimulus as part of a behavioral
avoidance test (described below). Important outcomes
included: general fear (global apprehension regarding a
host of situations and objects), compliance, parent fear,
pain, distress, procedure outcomes, memory, and preferences. General fear was also measured through multi-item
questionnaires. It is important to note that given the targeted nature of exposure-based interventions to the speciﬁc
feared stimulus, a reduction in general fear is not necessarily expected. A behavioral avoidance test or BAT (also
known as a behavioral approach test or task [The term
“behavioral avoidance test” was chosen for consistency
with Öst’s terminology; his work comprises much of the
review.]) was typically used to measure compliance; in a
BAT, the individual is asked to complete successive steps or
tasks of engagement with the feared stimulus and is scored
according to the number or percentage of steps successfully
completed. Fainting was measured by observer report of
fainting behavior during a BAT. Where possible, analyses
were separated by age (children vs. adults). Table 1 presents
the included clinical questions as well as critically important
and important outcomes included in the review.
If more than 1 indicator of an outcome was available
(eg, 2 or more questionnaires on speciﬁc fear), they were
combined using established approaches before meta-analysis.43 As part of each article extraction, Cochrane’s risk of
bias tool (https://bmg.cochrane.org/assessing-risk-biasincluded-studies) was applied on an outcome level. Data
were pooled using the RevMan software program (version
5.2, Cochrane Collaboration, Copenhagen, Denmark)
using a random eﬀects model; standardized mean diﬀerence
(SMD) for continuous data or relative risk for dichotomous
data along with 95% conﬁdence intervals (CI) were used to
assess the eﬀectiveness of an intervention. If data were
unavailable in the published paper, eﬀorts were made to
contact the authors for more information, or calculations
were made from available data on a restricted basis using
accepted formulae (eg, means and SDs were calculated

2015 Wolters Kluwer Health, Inc. All rights reserved.
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Additional records identified
through other sources
(n = 138)

Records identified through
database searching
(n = 114251)
Identification



Total records retrieved
(n = 114389)

Screening

Duplicate references
(n = 32155)
Full-text articles excluded
due to non-randomized
design (n = 42); incorrect
population (n = 16);
insufficient levels of fear,
unsystematic screening
(n = 3); intervention differs
from clinical question or
does not contain relevant
outcome (n = 21)

Screened for eligibility
(n = 82234)

Included

The remainder were not
relevant/outside of scope

Studies included in
systematic review
(n = 11)

Duplicate data
(n = 0)

FIGURE 1. Flow of studies.

from medians and ranges) or estimated from graphs.44 I2
and w2 tests were used to assess statistical heterogeneity.
The GRADE assessment of quality was used to summarize
quality across studies using the GRADE proﬁler software
(version 3.6.1); footnotes were used as explanatory aids.

RESULTS
Figure 1 shows the ﬂow of studies from database
searching to inclusion in the current review. Eleven studies
examining exposure-based treatments were retained for inclusion in the review and are described in Table 2. Six of the
included trials focused on children, with the remainder enrolling
adults only. One of the trials46 used a crossover design. However, only data from after completion of the ﬁrst treatment were
retained and, as a consequence, the included data represent a
parallel, between-groups design. The remaining 10 trials40–42,45,47–52 used a parallel groups design with at least 2
treatment arms; for the 3 trials which used waitlist control
groups that received treatment before the long-term follow-up,
only data collected before the waitlist control group was
randomized to active treatments were included in analyses.40–42
Notable sources of exclusion were as follows (note that
some citations could fall within more than 1 category but for
clarity of reporting are described in the most applicable category): (1) nonrandomized design including case studies
investigating exposure-based interventions (n = 37)21,53–88 or
case series (n = 5)31,89–92; (2) incorrect population including

S112 | www.clinicalpain.com

RCTs with children with nonspeciﬁc phobias (n = 2; eg, social
phobia, agoraphobia)93,94 or adults with general or global
dental fear, which is seen as a distinct issue29 (n = 2)95,96; (3)
incorrect population including muscle tension techniques
explored in nonfearful populations (n = 3),97–99 as well as a
series of studies examining the muscle tension technique in
voluntary blood donors (individuals who would volunteer to
give blood are seen as unlikely to have high levels of needle
fear100; n = 9)101–109; (4) insuﬃcient levels of fear, unsystematic screening process, or the potential that the fear was
adaptive (ie, presence of a fear of water when it was unclear
whether participants knew how to swim; n = 3)110–112; and (5)
treatment did not match clinical questions, dismantling trials,
or no relevant outcomes (n = 21).113–133

Quality of Studies and Risk of Bias
The risk of bias assessment (Cochrane methodology) for
each trial is shown in Table 3. All of the included trials had a
high risk of bias, which was primarily due to lack of blinding
of participants, personnel, and outcome assessor. Generally,
there were also insuﬃcient descriptions of sequence generation and allocation concealment to permit judgment.
Other potential sources of bias are noted using footnotes.

Overall Quality of Evidence and Treatment
Effects
A quantitative review of the eﬀects of each intervention
is provided below, organized by clinical question. Only the
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TABLE 2. Characteristics of the Trials Included in the Systematic Review

Procedure/
Injection
Details

Author Year,
Country

Population Enrolled, Design,
Setting

Intervention

Critical Outcomes

Should in vivo exposure-based therapy be used for children Z7 y with high levels of needle fear?
NA (this study was
In vivo exposure: 1 session r3 h; modeling,
N = 43
Flatt 2010,40
NA
not included in the
hierarchical exposure to feared stimuli targeting
Australia
10-step BAT 7-17 y
meta-analysis for
focus of catastrophic beliefs, contingency
Object of fear: various (n = 6
for
critical outcomes)
management, relaxation training; delivered by a
with
particular
psychologist (n = 17)
fear of needles; DSM-IV
object of
or
speciﬁc phobia); betweenfear
groups design*; single center, Psychoeducation and supportive psychotherapy:
length, number of sessions unclear; talking about
unclear setting
fears, learning diﬀerences between fear, anxiety
and phobias, learning etiology of phobias,
targeting enhancement of self-eﬃcacy, discussion
of exposure (but no actual exposure); delivered by
a psychologist (n = 15)w
or
Waitlist control (n = 11)*
Leutgeb 2012,45 NA
Austria
Viewing a
series of
pictures of
spiders
Muris 1998
(1),46 the
Netherlands

N = 32
8-13 y
Object of fear: spiders (DSM-IV
speciﬁc phobia); betweengroups design; single center,
unclear setting

N = 26
NA
10-step spider 8-17 y
Object of fear: spiders
BAT
(DSM-III-R simple phobia);
between-groups designz;
single center, university

In vivo exposure: 1 session r4 h; psychoeducation, Speciﬁc fear: SPQ-C,
SAM
modeling, hierarchical exposure to feared stimuli,
cognitive restructuring; delivered by a
psychologist (n = 15)
or
Waitlist control (n = 17)
Speciﬁc fear: SPQ-C
In vivo exposure: 1, 2.5 h session; rationale,
short form, SAMmodeling, hierarchical exposure to feared stimuli;
Spider, BAT-SAM
delivered by a behavioral scientist (n = 9)
or
Eye-movement desensitization and reprocessing: 1,
2.5 h session; imaginal exposure + horizontal eye
movements with cognitive restructuring; delivered
by a therapist (n = 9)w
or
Placebo: 1, 2.5 h session; computerized exposure to
feared stimuli (n = 8)y

Ollendick
NA
2009,41
BAT for
particular
Sweden and
object of
United States
fear

Speciﬁc fear: BATIn vivo exposure: 1 session r3 h; instruction,
N = 196
fear
modeling, hierarchical exposure to feared stimuli
7-16 y
targeting focus of catastrophic beliefs; delivered
Object of fear: various but
by therapists (n = 85)
excluded blood-injection injury
or
(DSM-IV speciﬁc phobia);
Education support therapy: 1 session r3 h; learning
between-groups design*;
deﬁnition of fear and phobia, etiology of phobias,
multicenter, unclear setting
physiological components, description of
“slipping” and how to handle it; delivered by
therapists (n = 70)w
or
Waitlist control (n = 41)*

Öst 2001 (1,
2),42 Sweden

In vivo exposure child alone: 1 session r3 h;
N = 60
instruction, modeling, hierarchical exposure to
7-17 y and parents in 1 group
feared stimuli targeting focus of catastrophic
Object of fear: various (n = 12 for
beliefs; delivered by psychologists (n = 21)
injections, n = 2 blood; DSMIV speciﬁc phobia); between- or
groups design*; single center, In vivo exposure child and parent: 1 session r3 h;
instruction, modeling, hierarchical exposure to
unclear setting
feared stimuli targeting focus of catastrophic
beliefs; delivered by psychologists (n = 20)
or Waitlist control (n = 19)*

NA
BAT for
particular
object of
fear

Should in vivo exposure-based therapy be used for adults with high levels of needle fear?
Öst 1991 (1),47 NA
In vivo exposure: 5 weekly 45 min to 1 h sessions;
N = 30
rationale for technique, hierarchical exposure to
Sweden
Surgical ﬁlm 18-55 y
feared stimuli; delivered by graduate students
Object of fear: blood-injectionBAT
(n = 10)
injury (DSM-III-R simple
or
phobia); between-groups

Speciﬁc fear: BATfear

Speciﬁc fear: MQ,
FSS-III-Blood, FQBlood/injury, BATFear

(Continued )
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TABLE 2. (continued)
Author Year,
Country

Procedure/
Injection
Details

Population Enrolled, Design,
Setting

Intervention

Critical Outcomes

Muscle tension: 5 weekly 45 min to 1 h sessions;
design; single center,
rationale for technique, practice of technique
outpatients of a mental hospital
without exposure to feared stimuli; delivered by
but unclear setting
graduate students (n = 10)
or
Muscle tension + in vivo exposure (applied tension):
5 weekly 45 min to 1 h sessions; rationale for
technique; practice technique without exposure
then with hierarchical exposure to feared stimuli;
delivered by graduate students (n = 10)w
Should multiple-session in vivo exposure-based therapy be used (rather than single session) for children Z7 y and adults with high levels of needle fear?
Öst 1992,48
Speciﬁc fear: IPS,
Single session in vivo exposure: 1 session r3 h;
N = 40
20-step
MQ, FSS-IIIpreparation, rehearsal, hierarchical exposure to
18-51 y
Sweden
venipuncInjection, BATfeared stimuli; delivered by psychologists (n = 20)
Object of fear: injections (DSMture BAT
Fear
III-R simple phobia); between- or
Multiple-session in vivo exposure: 5 weekly 1 h
groups design; single center,
sessions; preparation, rehearsal, hierarchical
outpatients of a mental hospital
exposure to feared stimuli; delivered by
but unclear setting
psychologists (n = 19)
Vika 2009,49
Norway

Single session in vivo exposure: 1 session (length
13-step dental N = 55
NR); hierarchical exposure to feared stimuli
18-62 y
injection
targeting focus of catastrophic beliefs; delivered
Object of fear: intraoral injections
BAT
by dentists (n = 28)
(DSM-IV speciﬁc phobia);
between-groups design; single or
Multiple-session in vivo exposure: 5 weekly 1 h
center, university
sessions; hierarchical exposure to feared stimuli
targeting focus of catastrophic beliefs; delivered
by dentists (n = 26)

Speciﬁc fear: IPSAnxiety, MQ, BATFear

Should non in vivo (imaginal) exposure-based therapy be used for children Z7 y with high levels of needle fear?
Cornwall
Emotive imagery: 6 weekly 40 min sessions; variant Speciﬁc fear: Fear
N = 24
NA
1996,50
Thermometer,
of hierarchical imaginal exposure (includes
7-10 y
A darkness
FSSC-R-Unknown
imagining presence of a “superhero”); delivered by
Object of fear: darkness (DSMAustralia
tolerance
a psychologist (n = 12)
III-R simple phobia); betweentest (BAT)
or
groups design; single center,
Waitlist control (n = 12)
university psychology clinic
Muris 1998
(2),46 the
Netherlands

Speciﬁc fear: SPQ-C
In vivo exposure: 1, 2.5 h session; rationale,
N = 26
NA
short form, SAMmodeling, hierarchical exposure to feared stimuli;
10-step spider 8-17 y
Spider, BAT-SAM
delivered by a behavioral scientist (n = 9)w
Object of fear: spiders (DSM-IIIBAT
or
R simple phobia); betweengroups designz; single center, Eye-movement desensitization and reprocessing: 1,
2.5 h session; imaginal exposure + horizontal eye
university
movements with cognitive restructuring; delivered
by a therapist (n = 9)
or
Placebo: 1, 2.5 h session; computerized exposure to
feared stimuli (n = 8)y

Should non in vivo exposure-based therapy be used for adults with high
Heaton 2013,51 Receipt of
N = 84
18-68 y
United States
dental
Object of fear: dental injections
injection
and needles (assessed by 2
after
questionnaires); betweentreatment
groups design; multicenter,
dental clinics

Mohr 2005,52
Self-injection
United States
of
medication

levels of needle fear?
Speciﬁc fear: MISAR,
Computer exposure: 9 video segments of CARL
NS
program; completed in 1-3 45 min sessions;
relaxation training, cognitive distraction, positive
coping strategies, then hierarchical exposure to
feared stimuli with modeling (n = 34)
or
Educational pamphlet: information about comfort,
anesthetics, postoperative pain management
(control) (n = 34)

Imaginal exposure: 6 weekly sessions (length NR) of NA (this study was
N = 30
not included in the
SIAT; psychoeducation, progressive muscle
18-61 y with multiple sclerosis
meta-analysis for
relaxation, hierarchical imaginal exposure and
Object of fear: injections (inability
critical outcomes)
relaxation (systematic desensitization) to feared
to self-inject medication

(Continued )
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TABLE 2. (continued)
Author Year,
Country

Procedure/
Injection
Details

Population Enrolled, Design,
Setting
Z3 mo; 12/30 met DSM-IV
speciﬁc phobia of bloodinjection-injury); betweengroups design; university
multiple sclerosis center

Intervention

Critical Outcomes

stimuli, cognitive restructuring, in vivo attempt of
injection in fourth and ﬁfth sessions; delivered by
nurses (n = 15)
or
Telephone support: 6 wk (length NR) of education
on injection techniques and progressive muscle
relaxation; delivered by nurses (n = 15)

Should applied tension (exposure and muscle tension) be used for children Z7 y and adults with high levels of needle fear and fainting?
Speciﬁc fear: MQ,
Öst 1991 (2),47 NA
In vivo exposure: 5 weekly 45 min to 1 h sessions;
N = 30
FSS-III-Blood, FQrationale for technique, hierarchical exposure to
Sweden
Surgical ﬁlm 18-55 y
Blood/injury, BATfeared stimuli; delivered by graduate students
BAT
Object of fear: blood-injectionFear
(n = 10)
injury (DSM-III-R simple
or
phobia); between-groups
Muscle tension: 5 weekly 45 min to 1 h sessions;
design; single center,
rationale for technique, practice of technique
outpatients of a mental hospital
without exposure to feared stimuli; delivered by
but unclear setting
graduate students (n = 10)w
or
Muscle tension + in vivo exposure (applied tension):
5 weekly 45 min to 1 h sessions; rationale for
technique; practice technique without exposure
then with hierarchical exposure to feared stimuli;
delivered by graduate students (n = 10)
Studies were identiﬁed using the following notation: “First Author” “Year of Publication” (eg, Taddio 2014). If studies contributed to multiple analyses,
then “#” was added to enable their discernment (eg, Taddio 2014 [1]). If the same author published >1 study in the same year, then a lower case letter was
added after the ﬁrst article in the same year by the same author (eg, Taddio 2014 a[1]).
*Data for waitlist control only available at posttreatment time-point; waitlist control randomized to active treatment condition(s) before longer term
follow-up. Only data before waitlist control randomization into active condition(s) were included, thus design is considered parallel (between-groups).
wThese data were not included in analyses for this question.
zOnly between-groups data following the completion of the ﬁrst treatment were included (ie, omitted crossover data collected after all groups received
traditional exposure treatment).
yMuris et al46: the authors considered the computer-based exposure treatment to be a placebo or control group; however, this is problematic.
Intervention: CARL, Computer Assisted Relaxation Learning; SIAT, Self-Injection Anxiety Therapy. Outcomes: BAT, Behavioral Avoidance Test (also
known as a Behavioral Approach Test or Task); BAT-SAM, Self-Assessment Manikin during the Behavioral Avoidance Test; FQ-Blood/injury, Fear
Questionnaire—Blood/injury subscale; FSS-III-Blood, Fear Survey Schedule Third Edition—Blood subscale; FSS-III-Injection, Fear Survey Schedule Third
Edition—Injection item; FSS-R-Unknown, Fear Survey Schedule Revised—Fear of the Unknown subscale; IPS, Injection Phobia Scale; IPS-Anxiety, Injection
Phobia Scale—Anxiety subscale; MISAR, Modiﬁed Interval Scale of Anxiety Response; MQ, Mutilation Questionnaire; NS, Needle Survey; SAM, SelfAssessment Manikin; SAM-Spider, fear of spiders in general; SPQ-C, Spider Phobia Questionnaire for Children. Other: NA, not applicable; NR, not reported.

results of critical outcomes are reported in text; however, the
important outcomes for which data are available are named
to guide readers. All results for both critically important and
important outcomes are included as Supplemental Digital
Content including GRADE Evidence Proﬁles and Summary
of Findings tables (Tables, Supplemental Digital Content 1
to 6, http://links.lww.com/CJP/A225, http://links.lww.com/
CJP/A226,
http://links.lww.com/CJP/A227,
http://links.
lww.com/CJP/A228, http://links.lww.com/CJP/A229, http://
links.lww.com/CJP/A230) and accompanying Forest plots
(Figures, Supplemental Digital Content 7 to 12, http://links.
lww.com/CJP/A231, http://links.lww.com/CJP/A232, http://
links.lww.com/CJP/A233, http://links.lww.com/CJP/A234, http://
links.lww.com/CJP/A235, http://links.lww.com/CJP/A236).
It is important to note that no trials were identiﬁed that were
speciﬁc to vaccine injections. Table 4 presents a summary of
the ﬁndings for critical outcomes.

Should In Vivo Exposure-based Therapy be Used for
Children 7 Years and Above With High Levels of
Needle Fear?
No trials were identiﬁed that: (1) examined in vivo
exposure-based therapy speciﬁcally for children with high
Copyright
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levels of needle fear (including blood-injection-injury phobia), or (2) reported results separately for children with
needle-related fear. Thus, 5 trials40–42,45,46 with 263 children
aged 7 to 17 years meeting diagnostic criteria for a speciﬁc
phobia according to the edition of the Diagnostic and
Statistical Manual of Mental Disorders current at the time
of the study were included in the analysis. In Flatt and
King,40 6 of 43 participants had a fear of needles, whereas
in Öst et al,42 12 of the 60 participants had a fear of
injections and 2 had a fear of blood; the remaining participants had a variety of speciﬁc phobias including spiders,45,46 enclosed spaces, or animals.41,42 One study41
excluded participants with blood-injection-injury phobia.
Treatment was delivered in a single session ranging
between 2.5 and 3 hours in 4 of the studies40–42,46 and 4 hours in
the remaining study.45 All the treatments were modeled after
Öst’s28 “One session treatment” and included modeling and
hierarchical exposure to the feared stimuli; 4 of the trials40–42,45
speciﬁed some degree of cognitive restructuring or targeting of
the catastrophic cognition. Comparison groups were waitlist
control40–42,45 or a “placebo” group of a computerized exposure
to spiders.46 In vivo exposure-based therapy demonstrated
beneﬁt on speciﬁc fear (4 trials; n = 235; SMD: 1.71 [95% CI:

2015 Wolters Kluwer Health, Inc. All rights reserved.

www.clinicalpain.com |

S115

Clin J Pain

McMurtry et al

2.72, 0.7]) (Table, Supplemental Digital Content 1, http://
links.lww.com/CJP/A225 and Figure, Supplemental Digital
Content 7, http://links.lww.com/CJP/A231). Important outcomes with data shown in the supplemental digital content
(Table, Supplemental Digital Content 1, http://links.lww.com/
CJP/A225 and Figure, Supplemental Digital Content 7, http://
links.lww.com/CJP/A231) include general fear, compliance
(using a BAT), child satisfaction, and parent satisfaction.

Should In Vivo Exposure-based Therapy be Used for
Adults With High Levels of Needle Fear?
One trial with 20 adult participants diagnosed with
blood-injection-injury phobia (excluding those with only an
injection phobia) according to the DSM-III-R134 was
included in this analysis.47 Treatment was given in 5 weekly
sessions of approximately 45 minutes and included hierarchical exposure to the feared stimuli. The comparison
group was trained in muscle tension but did not undergo
exposure. In vivo exposure-based therapy showed beneﬁt
on speciﬁc fear posttreatment (n = 20; SMD: 1.09
[ 2.04, 0.14]) but not at 1-year follow-up (n = 20; SMD:
0.28 [ 1.16, 0.6]) (Table, Supplemental Digital Content
2, http://links.lww.com/CJP/A226 and Figure, Supplemental Digital Content 8, http://links.lww.com/CJP/A232).
Important outcomes with data shown in the supplemental
digital content (Table, Supplemental Digital Content 2,
http://links.lww.com/CJP/A226 and Figure, Supplemental
Digital Content 8, http://links.lww.com/CJP/A232) include
each of the following at posttreatment and 1-year followup: general fear, fainting, and compliance (using a BAT).

Should Multiple-session In Vivo Exposure-based
Therapy be Used (Rather Than Single Session) for
Children 7 Years and Above and Adults With High
Levels of Needle Fear?
Two trials with 93 adults who were fearful of injections
were included in this analysis comparing multiple and single
sessions of in vivo exposure.48,49 Participants met the
diagnostic criteria for speciﬁc phobia according to the version of the Diagnostic and Statistical Manual of Mental
Disorders that was in use at the time of the study. According
to study descriptions, both treatments followed Öst’s treatment principles28,42; in vivo exposure consisted of either
preparation, rehearsal, hierarchical exposure to feared
stimuli,48 or hierarchical exposure to feared stimuli targeting
focus of catastrophic beliefs.49 Multiple-session in vivo
exposure was given over 5 weekly 1 hour sessions in both
trials; the 1 session treatment was maximized to 3 hours in 1
trial48 but the length of time was not reported for the other
trial.49 Results were mixed for the critical outcome of speciﬁc fear (Table, Supplemental Digital Content 3, http://
links.lww.com/CJP/A227 and Figure, Supplemental Digital
Content 9, http://links.lww.com/CJP/A233). Multiple-session in vivo exposure-based therapy was superior to single
session exposure for the reduction of speciﬁc fear measured
posttreatment (n = 93; SMD: 0.66 [1.08, 0.24]) but
not at 1-year follow-up (n = 83; SMD: 0.37 [0.87,
0.13]). Data for the following important outcomes measured
at 2 time-points (posttreatment, 1-year follow-up) are presented in the supplemental digital content (Table, Supplemental Digital Content 3, http://links.lww.com/CJP/A227
and Figure, Supplemental Digital Content 9, http://links.
lww.com/CJP/A233): general fear, compliance (using a
BAT), and fainting. Compliance with a voluntary blood
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donation or voluntary dental injection over the 12-month
follow-up period is also summarized.

Should Imaginal Exposure-based Therapy be Used for
Children 7 Years and Above With High Levels of
Needle Fear?
No trials were identiﬁed that studied children with a
fear of needles or a related phobia. Thus, trials of other
speciﬁc phobias were sought. Two trials with 41 children
aged 7 to 17 years with phobias of spiders or darkness
(diagnosed according to the DSM-III-R134) were included
in the analysis.46,50 In 1 study,50 children received 6 weekly
40-minute sessions of “emotive imagery” therapy during
which they engaged in a variant of imaginal hierarchical
exposure in which the child was supported by his or her
favorite superhero; the comparator was a waitlist control
group. Of note, although the authors describe their intervention as focusing on imaginal exposure, the children were
rewarded for initiating in vivo exposure between sessions.50
In the other study,46 children received a single 2.5-hour
session of eye-movement desensitization and reprocessing
therapy that included imaginal exposure combined with
rapid horizontal eye movements and cognitive restructuring; the comparison group was considered a placebo group
by the authors but consisted of 2.5 hours of computerdelivered exposure to the feared stimuli ranging in degree of
realism (eg, cartoon-like spiders vs. ones that appeared
more real). Imaginal exposure-based therapy led to a
reduction in speciﬁc fear posttreatment (both trials; n = 41;
SMD: 0.88 [ 1.7,  0.05]) and at 3-month follow-up
(1 trial50; n = 24; SMD: 0.89 [ 1.73, 0.04]) (Table,
Supplemental Digital Content 4, http://links.lww.com/CJP/
A228 and Figure, Supplemental Digital Content 10, http://
links.lww.com/CJP/A234). Data for the following important outcomes measured at 2 time-points (posttreatment,
3-month follow-up) are presented in the supplemental
digital content (Table, Supplemental Digital Content 4,
http://links.lww.com/CJP/A228 and Figure, Supplemental
Digital Content 10, http://links.lww.com/CJP/A234): general fear, distress (parent-rated), and compliance (using a
BAT).

Should Non In Vivo Exposure-based Therapy be Used
for Adults With High Levels of Needle Fear?
Two studies of adults with high levels of fear were
included in this analysis.51,52 One study51 included 84 otherwise healthy adults who were highly fearful and avoidant
of dental injections and needles (assessed by 2 questionnaires). The other trial52 included 30 adults with multiple sclerosis who were afraid of injections and unable to
perform necessary self-injections of their medication for at
least 3 months; 12 of the 30 participants met diagnostic
criteria for blood-injection-injury phobia according to the
DSM-IV.135 In Heaton et al51 participants received computer-delivered exposure through a specialized program
designed to be completed in 1 to 3, 45-minute sessions; the
content of the program included relaxation training, cognitive distraction, positive coping strategies, and hierarchical exposure with modeling. The comparison group
received an educational pamphlet.51 In Mohr et al,52 participants engaged in 6 weekly sessions (length of each session was not reported) involving psychoeducation, progressive muscle relaxation, hierarchical imaginal exposure
and relaxation, cognitive restructuring, and in vivo injection attempts in the fourth and ﬁfth sessions. The
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TABLE 3. Assessment of Risk of Bias of Included Trials for Critical Outcomes

Adequate
Sequence
Generation

Free of
Selective
Reporting

Free of
Other
Bias

Overall
Risk

Should in vivo exposure-based therapy be used for children Z7 y with high levels of needle fear?
NA
NA
NA
NA
NA
Flatt 201040
Unclear
Unclear
No
No
Yes
Leutgeb 201245
46
Unclear
Unclear
No
No
Yes
Muris 1998 (1)
Yes
Unclear
No
No
Yes
Ollendick 200941
Unclear
Unclear
No
No
Yes
Öst 2001 (1, 2)42

NA
Yes
Yes
Yes
Yes

NA
Yes
Unclear*
Now
Yes

NA
High
High
High
High

Should in vivo exposure-based therapy be used for adults with high levels of needle fear?
Unclear
Unclear
No
No
Öst 1991 (1)47

Yes

Yes

High

References

Blinding of
Allocation Participants and
Concealment
Personnel

Blinding of
Outcome
Assessment

Incomplete
Outcome Data
Addressed

Yes

Should multiple-session in vivo exposure-based therapy be used (rather than single session) for children Z7 y and adults with high levels of needle
fear?
Unclear
Unclear
No
No
Yes
Yes
Yes
High
Öst 199248
Yes
Unclear
No
No
Yes
Yes
Yes
High
Vika 200949
Should non in vivo (imaginal) exposure-based therapy be used for children Z7 y with high levels of needle fear?
Unclear
Unclear
No
No
Unclear
Yes
Cornwall 199650
Unclear
Unclear
No
No
Yes
Yes
Muris 1998 (2)46
Should non in vivo exposure-based therapy be used for adults with high levels of needle fear?
Yes
Yes
No
No
Unclear
Heaton 201351
NA
NA
NA
NA
NA
Mohr 200552

Yesz
NA

Yes
Unclear*

High
High

Yes
NA

High
NA

Should applied tension (exposure and muscle tension) be used for children Z7 y and adults with high levels of needle fear and fainting?
Unclear
Unclear
No
Unclear
Yes
Yes
Yes
High
Öst 1991 (2)47
*Diﬀerent therapists were used for the various groups.
wOutcome data are collapsed across country but there were baseline diﬀerences in the clinician-severity rating of the phobia (US > Sweden) and percentage
of steps completed on the BAT (US > Sweden).
zHeaton et al51: necessary data provided by the authors.
NA, this study was not included in the meta-analysis for critical outcomes for this question.

comparison group received 6 weeks of telephone support,
including education on injection techniques and progressive
muscle relaxation. Critically important outcomes were only
available for Heaton et al.51 Non in vivo exposure reduced
speciﬁc fear (n = 68; SMD: 0.62 [ 1.11,  0.14]) but not
acute fear during a voluntary injection (n = 17; SMD: 0.18
[ 0.87, 1.23]) (Table, Supplemental Digital Content 5,
http://links.lww.com/CJP/A229 and Figure, Supplemental
Digital Content 11, http://links.lww.com/CJP/A235). The
supplemental digital content (Table, Supplemental Digital
Content 5, http://links.lww.com/CJP/A229 and Figure,
Supplemental Digital Content 11, http://links.lww.com/
CJP/A235) contains data for the important outcome of
compliance measured through voluntary dental injection or
self-injection of medication.

Should Applied Tension (Exposure and Muscle
Tension) be Used for Children 7 Years and Above and
Adults With High Levels of Needle Fear and Fainting?
One trial with adult participants diagnosed with
blood-injection-injury phobia (excluding those with only an
injection phobia) according to the DSM-III-R134 was
included in this analysis.47 Participants received 5 weekly
45 minutes to 1 hour sessions of applied tension (muscle
tension + exposure); treatment included outlining the
rationale for the technique, practicing muscle tension
without and then with (hierarchical) exposure to feared
stimuli.47 The comparison group received 5 weekly
45 minutes to 1 hour sessions of in vivo exposure. Thus, this
analysis compared 2 active treatments. Applied tension
showed beneﬁt on the critical outcome of fainting both
Copyright
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posttreatment (n = 20; SMD: 1.16 [ 2.12, 0.19]) and
at 1-year follow-up (n = 20; SMD:  0.97 [ 1.91, 0.03])
(Table, Supplemental Digital Content 6, http://links.
lww.com/CJP/A230 and Figure, Supplemental Digital
Content 12, http://links.lww.com/CJP/A236). Data for
important outcomes of speciﬁc fear, general fear, and
compliance at both time-points are presented in the supplemental digital content (Table, Supplemental Digital
Content 6, http://links.lww.com/CJP/A230 and Figure,
Supplemental Digital Content 12, http://links.lww.com/
CJP/A236).

DISCUSSION
This systematic review and meta-analysis is the ﬁrst to
examine the eﬃcacy of exposure-based interventions for the
reduction of fear in individuals with high levels of needle
fears or phobias across the lifespan. Consideration of this
vulnerable population within the context of vaccine injections is critical given their heightened risk for fears and
avoidance of medical care over their lifetime2–15,17,29,136 and
complements the other systematic reviews on vaccine pain
management in this series.137–142
There were no trials examining interventions speciﬁc
to the vaccination context (which is perhaps not surprising
given that these interventions need to take place outside of
this context) and limited trials of children with high levels
of needle fears or phobias, requiring us to include indirect
evidence from nonvaccination and non-needle contexts. To
our knowledge, there has been no published systematic
examination of high levels of fear with regard to diﬀerent
types of needle procedures. The included trials enrolled
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TABLE 4. Summary of Results for Critically Important Outcomes

Clinical Questions

Quality
Critical
Beneﬁt of
of
Outcomes* Interventionw Evidencez

Interventions for individual with high needle fear
Should in vivo
Fear
Yes
exposure-based
therapy be used for
children Z7 y with
high levels of needle
fear?

Very low

Should in vivo
exposure-based
therapy be used for
adults with high levels
of needle fear?

Fear

Mixed

Very low

Should multiple-session
in vivo exposurebased therapy be used
(rather than single
session) for children
Z7 y and adults with
high levels of needle
fear?

Fear

Mixed

Very low

Should non in vivo
(imaginal) exposurebased therapy be used
for children Z7 y
with high levels of
needle fear?

Fear

Yes

Very low

Should non in vivo
exposure-based
therapy be used for
adults with high levels
of needle fear?

Fear

Mixed

Very low

Should applied tension
(exposure and muscle
tension) be used for
children Z7 y and
adults with high levels
of needle fear and
fainting?

Fainting

Yes

Very low

*Includes results for the critical outcomes that were evaluated in
included studies only.
wThe results for the eﬀect of the intervention have been summarized
across all evaluated critical outcomes, and are expressed using the following
notation: Yes, beneﬁt was observed across all evaluated critical outcomes;
Mixed, beneﬁt was observed for one or more but not all evaluated critical
outcomes; No, no evidence of beneﬁt was observed for any of the evaluated
critical outcomes.
zReﬂects the lowest quality of evidence rating across all evaluated critical outcomes, whereby rankings range from high to moderate to low to very
low.

participants with elevated fear of a particular situation,
object (typically related to needles), or both and utilized
interventions that exposed them to their particular fear.
Findings suggest that in vivo exposure-based therapy is
eﬀective for reducing speciﬁc fear in children (7 y and
above) and adults. Among adults with high levels of needle
fears, there was limited eﬃcacy found for the superiority of
delivering in vivo exposure in multiple, shorter sessions (eg,
5  1 h) as compared with 1 relatively long session (eg, 3 h).
Non in vivo (imaginal, computer-based) exposure was also
found to have beneﬁt on speciﬁc fear among children and
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adults. Finally, among adults, applied tension (exposure + muscle tension) was found to have additive beneﬁcial eﬀects on fainting, over and above exposure alone.
Taken together, these ﬁndings support the use of these
exposure-based interventions for reducing fear and fainting,
respectively, among individuals with high levels of needle
fears or phobias.
Interestingly, in comparison with single sessions,
multiple sessions of in vivo exposure were only more eﬃcacious for reducing speciﬁc fear immediately posttreatment but not at 1-year follow-up; these results then provide
only limited support for the eﬃcacy of a longer mode of
delivery.48,49 Moreover, all of the trials of in vivo exposure
in children, which were found to be eﬃcacious for reducing
speciﬁc fear, were single session.40–42,45,46 Unlike multiple
sessions that are typically an hour in length and spread out
over several weeks, single sessions often involve several
hours (eg, 2.5 to 4 h; Öst’s traditional 1 session treatment is
typically maximized to 3 h28) of exposure treatment. This
results in the provision of a higher “dose” of treatment at
one point in time. It is important to note that even in the
single session approach, exposure still progresses in a
hierarchical manner. Although there may be individual
diﬀerences in terms of preferences, readiness, and tolerance
for high versus low doses of this treatment, these ﬁndings
suggest that eﬀective treatment of high needle fears or
phobias may need not be time intensive (ie, taking several
weeks or even months); in fact, 1 session approaches for the
treatment of a variety of speciﬁc phobias have increased in
popularity over time.143–145 Beyond relative eﬃciency and
feasibility, the utility of 1 session treatment of high levels of
needle fear could be particularly high in preparing a fearful
individual for required, imminent medical treatment.
The inclusion of physical interventions (applied tension) for the management of fainting in individuals with
high levels of needle fears was important given that this
response is common in those with an extreme fear of blood
and needles (70% and 56%, respectively29). In the vaccination context, fainting is particularly concerning given the
potential for injuries as a result of falling.146–149 There may
be several mechanisms underlying the eﬃcacy of applied
tension, including both physiological (raising blood pressure) and psychological (interoceptive exposure leading to
changes in cognitions about the uncontrollability of fainting) mechanisms. The evidence supports the additive beneﬁt
of muscle tension in addition to in vivo exposure in adults.
Most impressive were the long-term eﬀects found for
fainting posttreatment and at 1-year follow-up, which
speaks to the robustness of this technique. Although the
current ﬁndings were based on the single trial that answered
the clinical question, extant research also supports the use
of applied tension for a reduction in fainting in the context
of blood-injection-injury phobia.31,33,116,120 These ﬁndings
warrant replication in individuals spanning various age
groups to determine whether this technique can be developmentally tailored to younger populations.
Overall, there was a striking dearth of research
examining interventions for individuals with high levels of
needle fears or phobias. We included children and adults
with high levels of needle fear and or phobias undergoing
vaccination or other needle procedures, followed by the
next closest context. We included individuals with a diagnosis of blood-injection-injury phobia or another related
phobia (eg, injection phobia) as well as individuals with
high levels of needle fear and related functional impairment
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(eg, being unable to self-inject medicine for their chronic
illness management). There were limited trials of bloodinjection-injury phobia in adults and no trials in children.
In the absence of randomized or quasi-randomized controlled trials on individuals with high levels of needle fears
or phobias, we were required to rely on trials of individuals
with speciﬁc phobias that were unrelated to needles (eg,
spider and darkness phobias). Although only occurring for
children, this may threaten the generalizability of the current ﬁndings to needle contexts. Indeed, individuals with
phobias and high levels of fear are not a homogenous group
and their response to feared stimuli and intervention are
invariably inﬂuenced by the speciﬁc catastrophic cognitions
underlying their fears. In short, extrapolating ﬁndings from
non–needle-related contexts to the vaccination context is
potentially problematic. Nevertheless, this systematic
review oﬀers important, new knowledge about eﬀective fear
management in this vulnerable group that can be applied to
vaccination to guide future research in this area.
Needle phobia has fallen under the diagnostic umbrella of
blood-injection-injury phobia and substantial similarities
between individuals with phobias of blood and phobias of
injections have been documented.29 Nevertheless, given the
breadth of the diagnostic category, the speciﬁc focus of the fear
can be quite diverse across individuals (eg, seeing injuries or
mutilation vs. receiving a needle).17 Thus, we were limited in our
review by the ﬁeld’s conceptualization of the phobia. Disgust
sensitivity has been implicated in certain speciﬁc phobias,
including blood-injection-injury phobia.150,151 Blood and injury
stimuli (vs. injection) may be more likely to elicit disgust.152 In
fact, disgust may emerge due to fears of contamination150,151;
thus, the speciﬁc focus of fear may be critical (eg, is the individual fearful of the pain, being contaminated by the needle,
fainting, or something else?). Only one of the trials (focused on
children with spider phobias) included in the current review
measured disgust, ﬁnding that exposure reduced both fear and
disgust.45 It is important to note that even among people who
fear needles speciﬁcally, the focus of individuals’ fears may diﬀer
(eg, they may fear blood, injections, insertion of foreign substance into their bodies, and/or the medical context153). Diﬀerences in the focus of fear would be expected to inﬂuence ones’
response to particular interventions.
Fears of needles can extend beyond the needle context
and follow a chronic course17,29,136; therefore, longitudinal
examinations that include the postintervention time period
(weeks, months, and years later) are important. Unlike the
other reviews in this series, many of the trials of interventions for individuals with high needle fears or phobias
included long-term follow-up assessments as well as inclusion of other outcomes deemed to be important by stakeholders invested in vaccination (eg, compliance, fainting,
satisfaction). This was a strength of this systematic review.
Although immediate outcomes reﬂect the short-term eﬃcacy of an intervention, the overall utility of an intervention
is questionable if ﬁndings are not maintained over time. In
vivo exposure was found to have eﬀects on immediate
posttreatment outcomes; however, less support was found
for longer term outcomes (1 y posttreatment). Among
children, non in vivo exposure had eﬀects on speciﬁc fear
that were maintained at 3-month follow-up, and applied
tension had eﬀects on fainting that were maintained at
1-year follow-up. This suggests that while some of these
interventions have lasting eﬀects, some individuals with
high levels of needle fears or phobias may require additional intervention to retain reductions of fear over longer
Copyright
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periods of time. The use of booster sessions in cognitivebehavioral treatments for many disorders (eg, anxiety,
depression) is well known.154 Booster sessions may be
particularly important for individuals with a high level of
needle fear who may go relatively long periods without
being exposed to a needle procedure.
Pain was not included as an outcome in the included
trials (due to the indirectness of the evidence) but has
important implications for needle fears and should be
included in future research. The relationship between needle
pain and fear is likely reciprocal and should be further
delineated. An exploration of the likely complex etiology of
needle fears is presented elsewhere in this series.20 However,
most individuals with high needle fears or phobias can root
their fear back to 1 traumatic needle procedure in their
past.29,155,156 Early vicarious and instrumental learning
processes may make individuals more vulnerable to experiencing and perceiving greater pain during needle procedures.20,157 Conversely, individuals whose pain is poorly
managed during needle procedures are more likely to develop
increasingly fearful memories of the procedure158 that then
places them at risk for experiencing more distress at subsequent needle procedures.159 This can fuel a vicious selfperpetuating cycle of increased needle fear and pain over
time.157 Eﬀective pain management may serve to help prevent
needle fears from developing. In short, eﬀective management
of pain and fear may serve to reduce future fear and pain and
hold promise for preventing distress and impairment (eg,
noncompliance) over time. Given that concerns about pain
and fear are known contributors to vaccine hesitancy,12,16
eﬀective management of both is paramount.
Consideration of the strengths and limitations of this body
of work creates clear pathways for future research. High-quality
RCTs of exposure-based interventions with individuals with
high levels of needle fear are critically needed, for the vaccination context and otherwise. Ideally, these trials should: (1)
enroll suﬃcient numbers of participants in narrow age ranges to
adequately capture developmental diﬀerences; (2) assess and
report fainting history as well as the speciﬁc focus of the needle
fear (eg, pain from the needle, injection of a foreign substance)
both at baseline and in response to treatment; (3) clearly report
and connect the target(s) of the exposure with the focus of the
needle fear; and (4) continue to gather longitudinal data as well
as expanding the outcomes and follow-up time frame if possible
(eg, beyond 1 y) with and without booster sessions. Discussion
of implementation considerations is beyond the scope of the
present paper and the reader is directed to our clinical practice
guideline on the management of high levels of needle fear that
explores these issues in detail160; however, future research
should also be conducted on various delivery methods of these
interventions to enhance feasibility and uptake.
In conclusion, we applied a rigorous methodological
approach to conduct the ﬁrst systematic review of
exposure-based interventions for the reduction of fear in
individuals of all ages with high levels of needle fears or
phobias. No trials speciﬁcally examined interventions
implemented in the vaccination context and trials of individuals with high levels of needle fears or phobias were
limited. Support was found for the eﬃcacy of in vivo and
non in vivo exposure therapy for reducing speciﬁc fear in
individuals with high levels of needle fears or phobias.
Multiple sessions of in vivo exposure were not clearly
superior to single sessions. Applied tension was eﬃcacious
for reducing fainting in adults. These ﬁndings suggest that
these interventions hold promise for reducing vaccine
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injection fear in individuals who are particularly vulnerable
for experiencing fear and avoidance of medical care over
time.
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120. Öst L-G, Sterner U, Fellenius J. Applied tension, applied
relaxation, and the combination in the treatment of blood
phobia. Behav Res Ther. 1989;27:109–121.
121. Penfold K, Page AC. The effect of distraction on withinsession anxiety reduction during brief in vivo exposure
for mild blood-injection fears. Behav Ther. 1999;30:
607–621.
122. Weiss MR, McCullagh P, Smith AL, et al. Observational
learning and the fearful child: influence of peer models on
swimming skill performance and psychological responses. Res
Q Exerc Sport. 1998;69:380–394.
123. Cyna AM, Tomkins D, Maddock T, et al. Brief hypnosis for
severe needle phobia using switch-wire imagery in a 5-year old.
Paediatr Anaesth. 2007;17:800–804.
124. Weigold C. The use of hypnosis in the management of
needle phobia. Aust J Clin Exp Hypn. 2011;39:189–195.
125. Kleinhauz M, Eli I. When pharmacologic anesthesia is
precluded: the value of hypnosis as a sole anesthetic agent
in dentistry. Spec Care Dentist. 1993;13:15–18.
126. Moore KA. “Hypnosis or not?”: brief intervention with
hypodermic needle phobic. Aust J Clin Exp Hypn. 1992;20:
49–53.
127. Hoyle DE. Use of visual placebo in desensitization of a
needle-phobic child. J Dent Child. 1982;49:214–216.
128. Gow MA. Treating dental needle phobia using hypnosis. Aust
J Clin Exp Hypn. 2002;30:198–202.
129. Abramowitz EG, Lichtenberg P. Hypnotherapeutic olfactory
conditioning (HOC): case studies of needle phobia, panic
disorder, and combat-induced PTSD. Int J Clin Exp Hypn.
2009;57:184–197.
130. Dennis B. Care study: severe needle phobia. Midwives Chron.
1994;107:58–61.
131. Brenes GA, Milo KM. A pregnant woman’s fear of her baby.
Psychosomatics. 2000;41:531–534.
132. Morgan S. Brief hypnosis for needle phobia. Aust J Clin Exp
Hypn. 2001;29:107–115.
133. Medd DY. Fear of injections: the value of hypnosis in
facilitating clinical treatment. Contemp Hypn. 2001;18:
100–106.
134. American Psychiatric Association. Diagnostic and Statistical
Manual of Mental Disorders. Washington, DC: American
Psychiatric Association; 1987.
135. American Psychiatric Association. Diagnostic and Statistical
Manual of Mental Disorders. Washington, DC: American
Psychiatric Association; 1994.
136. Goisman RM, Allsworth J, Rogers MP, et al. Simple phobia
as a comorbid anxiety disorder. Depress Anxiety. 1998;7:
105–112.
137. Birnie KA, Chambers CT, Taddio A, et al. Psychological
interventions for vaccine injections in children and adolescents: systematic review of randomized and quasi-randomized
controlled trials. Clin J Pain. 2015;31(10S):S72–S89.
138. Boerner KE, Birnie KA, Chambers CT, et al. Simple
psychological interventions for reducing pain from common
needle procedures in adults: systematic review of randomized
and quasi-randomized controlled trials. Clin J Pain.
2015;31(10S):S90–S98.
139. Pillai Riddell R, Taddio A, McMurtry CM, et al. Psychological interventions for vaccine injections in young children 0

Copyright

r

2015 Wolters Kluwer Health, Inc. All rights reserved.

Clin J Pain

140.

141.

142.

143.

144.

145.

146.
147.

148.

149.



Volume 31, Number 10S, October 2015

to 3 years: systematic review of randomized controlled trials
and quasi-randomized controlled trials. Clin J Pain.
2015;31(10S):S64–S71.
Pillai Riddell R, Taddio A, McMurtry CM, et al. Process
interventions for vaccine injections: systematic review of
randomized controlled trials and quasi-randomized
controlled trials. Clin J Pain. 2015;31(10S):S99–S108.
Taddio A, Shah V, McMurtry CM, et al. Procedural and
physical interventions for vaccine injections: systematic
review of randomized controlled trials and quasi-randomized
controlled trials. Clin J Pain. 2015;31(10S):S20–S37.
Shah V, Taddio A, McMurtry CM, et al. Pharmacological
and combined interventions to reduce vaccine injection pain
in children and adults: systematic review and meta-analysis.
Clin J Pain. 2015;31(10S):S38–S63.
Davis TEI, Ollendick TH, Reuther ET, et al. One-session
treatment: principles and procedures with children and
adolescents. In: Davis TEI, ed. Intensive One-Session Treatment of Specific Phobias. New York, NY: Springer; 2012:
97–125.
Ollendick TH, Davis TEI. One-session treatment for specific
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